

CCHMC – COVID-19 Clinical Trials
Last Updated: November 13, 2020

PI	Division	Title	Funding Source
Gurjit Khurana Hershey	Asthma Research	Human Epidemiology and Response to SARS-COV-2 (HEROS)	NIH
Katherine Bowers	Biostatistics and Epidemiology	Serology of COVID-19 Patients and Contacts in Cincinnati, OH	CCTST C5G Award
Robert Frenck	Infectious Disease	A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2-RNA Vaccine Candidates Against COVID-19 in Healthy Adults	Pfizer
Robert Frenck	Infectious Disease	A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 (Astra Zeneca)	
Lara Danziger-Isakov	Infectious Disease	DAS181 for COVID-19: A Multicenter, Randomized, Placebo- Controlled, Double-Blind Study	Ansun BioPharma